HC Wainwright Has Bullish Forecast for NRXP FY2024 Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Investment analysts at HC Wainwright upped their FY2024 earnings per share estimates for NRx Pharmaceuticals in a research report issued on Monday, November 25th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings of ($1.75) per share for the year, up from their previous estimate of ($3.25). HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($3.25) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2024 earnings at ($0.20) EPS and FY2025 earnings at ($0.08) EPS.

NRXP has been the topic of a number of other research reports. Ascendiant Capital Markets boosted their target price on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the stock a “buy” rating in a research note on Thursday, September 12th. EF Hutton Acquisition Co. I raised NRx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 21st.

NRx Pharmaceuticals Trading Up 1.6 %

Shares of NRx Pharmaceuticals stock opened at $1.29 on Wednesday. The firm’s 50 day moving average is $1.38 and its 200 day moving average is $2.14. The firm has a market capitalization of $15.60 million, a PE ratio of -0.61 and a beta of 1.27. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $7.33.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Townsquare Capital LLC purchased a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned 0.14% of NRx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 4.27% of the stock is owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.